RxDoctor Payments Data

Simran Kaur, MD

Family Medicine · Bay City, MINPI 1649406349

Payments from drug & device makers

$660in general payments, 2019–2025

Across 12 payments — averaging $54.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$145
  • AbbVie$124
  • Lilly USA, LLC$107
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$106
  • AstraZeneca$80
  • GSK$28
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$660 in reported general payments places this provider in the 65th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$66,460
Medicare patients
247
Services billed
758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$116,879
TrulicityDulaglutide53$86,074
JardianceEmpagliflozin31$41,835
EliquisApixaban33$37,550
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$35,117
JanuviaSitagliptin Phosphate23$28,223
Atorvastatin Calcium445$5,670
SymbicortBudesonide/Formoterol Fumarate17$5,661
Rosuvastatin Calcium160$3,996
Albuterol Sulfate HfaAlbuterol Sulfate115$3,754
Levothyroxine Sodium278$3,666
Incruse ElliptaUmeclidinium Bromide11$3,644
Losartan Potassium229$2,943
Gabapentin147$2,578
Duloxetine Hcl59$2,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$116,87970 claims
Lilly USA, LLCTrulicity$107$86,07453 claims
GSKTrelegy Ellipta, Incruse Ellipta$28$38,76154 claims
AstraZenecaSymbicort$80$5,66117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Bay City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →